Cipher Pharmaceuticals Inc. (CPH)

Overview

Cipher Pharmaceuticals Inc., founded in 2000 and based in Mississauga, Canada, identifies itself as a specialty pharmaceutical company primarily operational within the Canadian borders. It has carved a niche for itself through the development, licensing, and acquisition of novel pharmaceutical products aimed at enhancing patient care across several therapeutic areas. The company's focused endeavor has been towards addressing severe skin conditions, pain management, and other specialized medical needs through a diverse portfolio of products, some of which are marked by their distinctive therapeutic effects.

Products and Services

Epuris (isotretinoin): Specially formulated as an oral retinoid for patients battling severe forms of nodular and/or inflammatory acne, acne conglobate, and particularly stubborn or recalcitrant acne types. This product underscores Cipher Pharmaceutical's commitment to addressing complex dermatological conditions.

Actikerall (Topical Solution): Designed to address the treatment needs for Grade I/II hyperkeratotic actinic keratosis, particularly those located on facial areas, the forehead, and the balding scalp. This topical solution is indicative of the company's expertise in developing treatments for skin conditions resulting from overexposure to the sun.

Ozanex: A topical treatment optimized for managing impetigo, showcasing Cipher Pharmaceuticals' ability to provide solutions for common, yet distressing, bacterial skin infections.

Vaniqa (Topical Cream): Specifically created as a cosmetic augmentation, this topical cream is applied to slow down the growth of unwanted facial hair in women, highlighting Cipher Pharmaceuticals' foray into cosmetic dermatology.

Durela: Reflecting the company's ventures into pain management, this opioid analgesic is prescribed for the management of moderate to moderately severe pain in adults, underlining the company's holistic approach to patient care.

Brinavess: A rapid-action treatment designed for the conversion of recent-onset atrial fibrillation to sinus rhythm in adults, this product is a testament to Cipher's innovative approaches in cardiology.

Aggrastat: This reversible GP IIb/IIIa inhibitor finds its use in patients experiencing Acute Coronary Syndrome, reinforcing the company's dedication to critical care and emergency medicine.

Partnership Products

• Absorica: An oral retinoid focusing on severe nodular and inflammatory acne treatments under licensing, further broadening Cipher's acne treatment lineup.
• Lipofen: Targeted as adjunctive therapy to diet for reducing lipid levels, specifically LDL-C, total-C, triglycerides, and Apo B, and increasing HDL-C in adults to manage triglyceride levels effectively.
• Conzip: Another addition to the pain management segment, this opioid agonist is indicated for the long-term management of moderate to moderately severe chronic pain in adults.

Pipeline Products

• MOB-015: A topical formulation of terbinafine, currently undergoing phase 3 clinical trials, aimed at treating onychomycosis, showcasing Cipher's commitment to addressing fungal infections.
• CF-101 (Piclidenoson): Presently in phase 3 clinical trials for severe plaque psoriasis and rheumatoid arthritis, indicating the company's exploration into treatments for autoimmune diseases and skin conditions.
• DTR-001: A pre-clinical stage project developing a tattoo removal cream, highlighting ongoing innovation and expansion into cosmetic dermatology solutions.